Rodman David Malcom Buys Shares of MLYS $MLYS
Key Points
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Rodman David Malcom, Chief Medical Officer at Mineralys Therapeutics, Inc. ($MLYS), bought 6,349 shares at an average price of $1.08, for a total transaction of $6,856.92. The trade was disclosed in a Form 4 filing with the Securities and Exchange Commission.
Mineralys Therapeutics, Inc. Stock Down 7.2%
Shares of Mineralys Therapeutics, Inc. ($MLYS) traded around $23.75 on Saturday, down 7.2% for the day.
Mineralys Therapeutics, Inc. Earnings
Analysts Set New Price Targets
About Mineralys Therapeutics, Inc.
Mineralys Therapeutics, Inc., a biopharmaceutical company, develops medicines to target diseases driven by dysregulated aldosterone in the United States. It is developing lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by dysregulated aldosterone, such as hypertension, chronic kidney disease, and obstructive sleep apnea. The company was formerly known as Catalys SC1, Inc. and changed its name to Mineralys Therapeutics, Inc. in May 2020. Mineralys Therapeutics, Inc. was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.
Get Mineralys Therapeutics, Inc. alerts
New 13F filings, insider trades, and analyst moves on $MLYS, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.